WO2005053604A3 - Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees - Google Patents

Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees Download PDF

Info

Publication number
WO2005053604A3
WO2005053604A3 PCT/US2004/017855 US2004017855W WO2005053604A3 WO 2005053604 A3 WO2005053604 A3 WO 2005053604A3 US 2004017855 W US2004017855 W US 2004017855W WO 2005053604 A3 WO2005053604 A3 WO 2005053604A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies specific
associated antigen
cancer associated
antibodies
polynucleotides
Prior art date
Application number
PCT/US2004/017855
Other languages
English (en)
Other versions
WO2005053604A2 (fr
Inventor
Jing Ma
Yajun Guo
Original Assignee
Oncomax Acquisition Corp
Jing Ma
Yajun Guo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB2003101199264A external-priority patent/CN1279056C/zh
Application filed by Oncomax Acquisition Corp, Jing Ma, Yajun Guo filed Critical Oncomax Acquisition Corp
Priority to EP04776307A priority Critical patent/EP1631238A2/fr
Priority to JP2006533570A priority patent/JP2007535905A/ja
Priority to CA002528182A priority patent/CA2528182A1/fr
Priority to AU2004294893A priority patent/AU2004294893A1/en
Publication of WO2005053604A2 publication Critical patent/WO2005053604A2/fr
Priority to IL172242A priority patent/IL172242A0/en
Publication of WO2005053604A3 publication Critical patent/WO2005053604A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des anticorps qui sont spécifiques de l'antigène SM5-1 exprimé dans les mélanomes, le cancer du sein et les carcinomes hépatocellulaires ; ainsi que des polynucléotides codant ces anticorps. L'invention concerne en outre l'utilisation desdits anticorps et/ou polynucléotides dans le diagnostic et le traitement de tumeurs malignes.
PCT/US2004/017855 2003-06-06 2004-06-04 Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees WO2005053604A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04776307A EP1631238A2 (fr) 2003-06-06 2004-06-04 Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees
JP2006533570A JP2007535905A (ja) 2003-06-06 2004-06-04 癌関連抗原ｓｍ５−１の特異抗体およびその用途
CA002528182A CA2528182A1 (fr) 2003-06-06 2004-06-04 Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees
AU2004294893A AU2004294893A1 (en) 2003-06-06 2004-06-04 Antibodies specific for cancer associated antigen SM5-1 and uses thereof
IL172242A IL172242A0 (en) 2003-06-06 2005-11-29 Antibodies specific for cancer associated antigen sm5-1 and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN03129123.6 2003-06-06
CN03129123 2003-06-06
CN2003101199264 2003-11-25
CNB2003101199264A CN1279056C (zh) 2003-06-06 2003-11-25 肿瘤相关抗原sm5－1的特异性抗体及其应用
US10/722,849 US20050031617A1 (en) 2003-06-06 2003-11-26 Antibodies specific for cancer associated antigen SM5-1 and uses thereof
US10/722,849 2003-11-26
TW092133571 2003-11-28
TW092133571A TW200517122A (en) 2003-06-06 2003-11-28 Antibodies specific for cancer associated antigen SM5-1 and uses thereof

Publications (2)

Publication Number Publication Date
WO2005053604A2 WO2005053604A2 (fr) 2005-06-16
WO2005053604A3 true WO2005053604A3 (fr) 2006-02-09

Family

ID=42331655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/017855 WO2005053604A2 (fr) 2003-06-06 2004-06-04 Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees

Country Status (5)

Country Link
JP (1) JP2007535905A (fr)
AU (1) AU2004294893A1 (fr)
CA (1) CA2528182A1 (fr)
IL (1) IL172242A0 (fr)
WO (1) WO2005053604A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595387A (en) * 2005-08-11 2013-04-26 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
IL199534A (en) * 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2603524A1 (fr) 2010-08-14 2013-06-19 AbbVie Inc. Protéines de liaison bêta-amyloïdes
RU2556816C1 (ru) * 2014-03-12 2015-07-20 Открытое акционерное общество "Фармацевтический импорт, экспорт" (ОАО "Фармимэкс") Штамм клеток яичников китайского хомячка - продуцент рекомбинантного антитела против фактора некроза опухоли альфа человека
CN109627337B (zh) * 2018-12-29 2023-07-21 上海复宏汉霖生物技术股份有限公司 一种抗prlr的单克隆抗体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REINKE S ET AL: "Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma.", AMERICAN JOURNAL OF DERMATOLOGY., vol. 27, no. 5, 2005, pages 401 - 406, XP008058050 *
TREFZER U ET AL: "SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions.", ARCH DERMATOL RES., vol. 292, 2000, pages 583 - 589, XP002993817 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
WO2005053604A2 (fr) 2005-06-16
IL172242A0 (en) 2006-04-10
JP2007535905A (ja) 2007-12-13
AU2004294893A1 (en) 2005-06-16
CA2528182A1 (fr) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2005053604A3 (fr) Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees
WO2004058171A3 (fr) Anticorps anti-gpr64 et utilisations
WO2003101401A3 (fr) Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
WO2007081720A3 (fr) Procédés et compositions basés sur des micro-arn et s'appliquant au diagnostic, au pronostic et au traitement du cancer du poumon
WO2005123993A8 (fr) Profilage micromatriciel bactériophage de la réponse humorale à la maladie
WO2002092854A3 (fr) Genes exprimes dans le cancer du sein en tant que cibles therapeutique et de pronostic
WO2004060302A3 (fr) Methodes et compositions pour le diagnostic, le pronostic, et le traitement du cancer
WO2004001381A3 (fr) Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible
EP1742654A4 (fr) Anticorps anti-lfl2 pour le diagnostic, le pronostic et le traitement d'un cancer
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2003048301A3 (fr) Anticorps anti-hla-dr et leurs methodes d'utilisation
WO2008130887A8 (fr) Biomarqueurs du carcinome thyroïdien folliculaire et procédés d'utilisation de ceux-ci
AP2006003537A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy.
WO2004060304A3 (fr) Compositions et procedes pour la cancerotherapie
WO2005028498A3 (fr) Kid3 et anticorps de liaison a kid3
WO2002010436A3 (fr) Classification de pronostics de cancer du sein
WO2007033167A3 (fr) Compositions et methodes de detection et de traitement du cancer
TW200517122A (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
WO2006052975A3 (fr) Tumeurs de mdl-1 et procedes associes
WO2003080808A3 (fr) Nouvelles compositions et nouveaux procedes pour le cancer
WO2003026494A3 (fr) Galectines-1 et -4 dans le developpement des tumeurs
WO2005046602A3 (fr) Antagonistes des recepteurs du vegf
WO2004005351A3 (fr) Anticorps specifiques de neoplasme et utilisations associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172242

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2528182

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004776307

Country of ref document: EP

Ref document number: 2006533570

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004294893

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2622/KOLNP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004294893

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004776307

Country of ref document: EP